Event-Driven Stocks

Syneos Health, Inc.

Industrials · Services-Commercial Physical & Biological Research · DE · SEC filings ↗ · Compare ⊕

Signs● 4 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue$5.39B$5.21B$4.42B$4.68B$4.39B$2.67B
Operating income$403.2M$389.3M$293.1M$26.8M$10.2M−$28.9M
Net income$266.5M$234.8M$192.8M−$30.0M−$24.6M−$138.5M
Total assets$8.20B$8.24B$8.06B$7.45B$7.25B$7.29B
Total liabilities$4.70B$4.82B$4.82B$4.42B$4.40B$4.26B
Equity$3.50B$3.41B$3.24B$3.03B$2.86B$3.02B
EPS (diluted)$2.58$2.24$1.83$-0.29$-0.24$-1.85
Shares out.104.2M104.3M104.2M103.7M104.6M54.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
7.5%
Net margin
4.9%
Return on equity
7.6%
Return on assets
3.3%
Return on capital (ROCE)
6.2%
Liabilities / assets
57.4%
Debt / equity
1.35×
Book value / share
$33.53
Revenue growth (YoY)
3.5%
Net income growth (YoY)
13.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
1.35grey zone
Accruals / assets
−2.0%clean
Piotroski F-Score
9/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
82
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 100Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 4 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Altman Z″ in the grey zone
  • Operating margin is positive
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)